日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

在ALLEGRO临床开发项目中,接受利特西替尼治疗的斑秃患者的临床反应模式

King, B; Mirmirani, P; Lo Sicco, K; Ramot, Y; Sinclair, R; Asfour, L; Ezzedine, K; Paul, C; Ohyama, M; Edwards, R A; Bonfanti, G; Kerkmann, U; Wajsbrot, D; Ishowo-Adejumo, R; Zwillich, S H; Lejeune, A

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

丹麦一项基于登记数据的队列研究:接受医院治疗的斑秃患者的感染率、恶性肿瘤发生率、心血管事件发生率和死亡率

Sørensen, Sissel Brandt Toft; George, Prethibha; Jagun, Oladayo; Wolk, Robert; Napatalung, Lynne; Zwillich, Samuel H; Iversen, Lars; Ehrenstein, Vera

Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment

利用患者意愿指导利妥昔单抗治疗斑秃的剂量选择

Hauber, Brett; Whichello, Chiara; Mauer, Jonathan; Law, Ernest; Trapali, Myrto; Whalen, Edward; Wajsbrot, Dalia; Krucien, Nicolas; Tervonen, Tommi; Zwillich, Samuel H; Wolk, Robert

A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata

一项 2a 期研究,旨在调查利特西替尼对斑秃成人患者脑干听觉诱发电位和表皮内神经纤维组织学的影响

Anderson, Samira; Cavaletti, Guido; Hood, Linda J; Polydefkis, Michael; Herrmann, David N; Rance, Gary; King, Brett; McMichael, Amy J; Senna, Maryanne M; Kim, Brian S; Napatalung, Lynne; Wolk, Robert; Zwillich, Samuel H; Schaefer, Gregor; Gong, Yankun; Sisson, Melanie; Posner, Holly B

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

ALLEGRO 临床试验项目中口服 JAK3/TEC 家族激酶抑制剂 Ritlecitinib 治疗斑秃的综合安全性分析

Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune2

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

美国医疗保险数据库中斑秃患者队列的感染、恶性肿瘤、血栓栓塞和心血管事件发生率

George, Prethibha; Jagun, Oladayo; Liu, Qing; Wentworth, Charles; Napatalung, Lynne; Wolk, Robert; Anway, Susan; Zwillich, Samuel H

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6

托法替尼治疗类风湿性关节炎:早期疾病活动度未见明显改善以及6个月时达到低疾病活动度的概率

van Vollenhoven, Ronald F; Lee, Eun Bong; Fallon, Lara; Zwillich, Samuel H; Wilkinson, Bethanie; Chapman, Douglass; DeMasi, Ryan; Keystone, Edward

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

简报:托法替尼治疗类风湿性关节炎的缓解率:不同缓解标准的比较

Smolen, Josef S; Aletaha, Daniel; Gruben, David; Zwillich, Samuel H; Krishnaswami, Sriram; Mebus, Charles

Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial

托法替尼联合传统改善病情抗风湿药物治疗活动性类风湿关节炎患者:一项 III 期随机对照试验的患者报告结果

Strand, Vibeke; Kremer, Joel M; Gruben, David; Krishnaswami, Sriram; Zwillich, Samuel H; Wallenstein, Gene V

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

托法替尼与甲氨蝶呤治疗类风湿性关节炎:随机 III 期 ORAL Start 试验的患者报告结局

Strand, Vibeke; Lee, Eun Bong; Fleischmann, Roy; Alten, Rieke E; Koncz, Tamas; Zwillich, Samuel H; Gruben, David; Wilkinson, Bethanie; Krishnaswami, Sriram; Wallenstein, Gene